DZ Bank reiterated their neutral rating on shares of Fresenius Medical Care AG & Co. (NYSE:FMS) in a research report sent to investors on Thursday morning, Borsen Zeitung reports.
FMS has been the topic of a number of other reports. Barclays reiterated a hold rating and set a $14.00 target price on shares of MACOM Technology Solutions in a research report on Thursday, June 20th. Zacks Investment Research cut First Merchants from a hold rating to a sell rating in a report on Monday, July 1st. Commerzbank reissued a hold rating and issued a $54.00 price target on shares of Fresenius Medical Care AG & Co. in a report on Thursday, May 9th. Finally, Royal Bank of Canada cut their price target on from GBX 3,000 ($39.20) to GBX 2,900 ($37.89) and set an outperform rating for the company in a report on Thursday, June 6th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $53.05.
Fresenius Medical Care AG & Co. stock opened at $39.32 on Thursday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.79 and a current ratio of 1.02. Fresenius Medical Care AG & Co. has a 1-year low of $30.99 and a 1-year high of $53.40. The stock has a market capitalization of $24.13 billion, a P/E ratio of 17.32, a PEG ratio of 2.79 and a beta of 1.43. The company has a 50 day simple moving average of $38.40.
Institutional investors have recently added to or reduced their stakes in the stock. Harvest Group Wealth Management LLC acquired a new stake in Fresenius Medical Care AG & Co. during the first quarter worth about $29,000. Osborn Williams & Donohoe LLC purchased a new stake in shares of Fresenius Medical Care AG & Co. in the first quarter worth about $42,000. Magellan Asset Management Ltd boosted its position in shares of Fresenius Medical Care AG & Co. by 52.3% in the fourth quarter. Magellan Asset Management Ltd now owns 1,433 shares of the company’s stock worth $46,000 after buying an additional 492 shares during the period. QS Investors LLC purchased a new stake in shares of Fresenius Medical Care AG & Co. in the fourth quarter worth about $58,000. Finally, Rehmann Capital Advisory Group boosted its position in shares of Fresenius Medical Care AG & Co. by 46.7% in the first quarter. Rehmann Capital Advisory Group now owns 2,565 shares of the company’s stock worth $104,000 after buying an additional 817 shares during the period. Hedge funds and other institutional investors own 1.46% of the company’s stock.
About Fresenius Medical Care AG & Co.
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Story: How to Use a Moving Average for Trading
Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.